| 117 -7.98 (-6.39%) | 11-07 10:47 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 149.52 |
1-year : | 164.53 |
| Resists | First : | 128.01 |
Second : | 140.86 |
| Pivot price | 126.64  |
|||
| Supports | First : | 107.22 |
Second : | 89.2 |
| MAs | MA(5) : | 123.36 |
MA(20) : | 123.42 |
| MA(100) : | 119.06 |
MA(250) : | 97.8 |
|
| MACD | MACD : | 2.1 |
Signal : | 3 |
| %K %D | K(14,3) : | 35.5 |
D(3) : | 41.6 |
| RSI | RSI(14): 47 |
|||
| 52-week | High : | 145.5 | Low : | 55 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ TMDX ] has closed above bottom band by 21.4%. Bollinger Bands are 10.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 125.78 - 126.38 | 126.38 - 126.93 |
| Low: | 119.28 - 119.97 | 119.97 - 120.61 |
| Close: | 123.82 - 124.98 | 124.98 - 126.03 |
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Wed, 05 Nov 2025
Advisors Preferred LLC Takes $618,000 Position in TransMedics Group, Inc. $TMDX - MarketBeat
Wed, 05 Nov 2025
Why TransMedics Group (TMDX) Is Up After Raising 2025 Revenue Outlook and Posting Strong Q3 Results - simplywall.st
Tue, 04 Nov 2025
TransMedics Group, Inc. (NASDAQ:TMDX) Shares Could Be 47% Below Their Intrinsic Value Estimate - 富途牛牛
Mon, 03 Nov 2025
Wakefield Asset Management LLLP Makes New Investment in TransMedics Group, Inc. $TMDX - MarketBeat
Sun, 02 Nov 2025
Spire Wealth Management Makes New $679,000 Investment in TransMedics Group, Inc. $TMDX - MarketBeat
Fri, 31 Oct 2025
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 34 (M) |
| Shares Float | 33 (M) |
| Held by Insiders | 2.9 (%) |
| Held by Institutions | 110.2 (%) |
| Shares Short | 7,970 (K) |
| Shares Short P.Month | 8,390 (K) |
| EPS | 1.98 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 9.35 |
| Profit Margin | 13.4 % |
| Operating Margin | 23.2 % |
| Return on Assets (ttm) | 5.8 % |
| Return on Equity (ttm) | 28.2 % |
| Qtrly Rev. Growth | 37.7 % |
| Gross Profit (p.s.) | 9.31 |
| Sales Per Share | 15.58 |
| EBITDA (p.s.) | 2.94 |
| Qtrly Earnings Growth | 162.5 % |
| Operating Cash Flow | 115 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | 60.83 |
| PEG Ratio | 0 |
| Price to Book value | 12.88 |
| Price to Sales | 7.72 |
| Price to Cash Flow | 35.62 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|